• Efficacy data

    Joint damage

    In the FUTURE 2 clinical trial ,in a mixed population: 2/3 biologic-naive and 1/3anti–TNF-αinadequate responders 1 ACR20 responses at Week 16 in the mixed...

  • About Xolair

    Indication & Posology

    Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. The recommended dose is 300 mg by subcutaneous injection every four weeks 1 . Prescribers are advised to periodically reassess the need for continued therapy.

    Reference: 1. Xolair Summary of Product Characteristics. July 2020.

    Data

    Think IgE, Think Xolair IgE plays a key role in the sensitization and activation of mast cells, leading them to release histamine and other mediators 9 . In patients with CSU, IgE causes inappropriate activation of mast cells 9 . Xolair directly targets IgE, neutralizing it and preventing histamine release 7,9,10

    Efficacy

  • Safety and tolerability

    Over 200,000 patients with Cosentyx exposure 1 Cosentyx is a fully human monoclonal antibody with favorable long-term safety profile 2, 5 and almost 0 immunogenicity 2

    >4500* patients...

  • Healthcare Professional Resources

    Dry eye disease (DED) is a multifactorial debilitating disorder of the tear film due to tear quality deficiency or tear evaporation. Estimates suggest 5-50% of the population may have DED

    The science around DED is poorly understood and...

  • Novartis Future in Lipid Management

    Inclisiran

    Inclisiran, an investigational cholesterol-lowering treatment, was added to the pipeline from the Novartis acquisition of The Medicines Company. Inclisiran will potentially be the first and only LDL-C-lowering...

  • EXPAND

    EXPAND: Siponimod Versus Placebo in Secondary Progressive multiple Sclerosis (EXPAND): a double blind, randomized phase III study.

    MAYZENT WAS STUDIED IN A BROAD RANGE OF ACTIVE SPMS PATIENTS 18

    * SPMS with active disease was...

  • Safety data

    Consistent safety profile

    Variable

    PREVENT 1,2 MEASURE 1 3,4 MEASURE 2 3,5

    Secukinumab

    150 mg LD (N = 185)

    Secukinumab

    150 mg NL (N = 184)

    Placebo (N = 186...

  • Safety Data

    Consistent safety profile

    Variable

    PREVENT 1,2 MEASURE 1 3,4 MEASURE 2 3,5

    Secukinumab

    150 mg LD (N = 185)

    Secukinumab

    150 mg NL (N = 184)

    Placebo (N = 186...

  • Neurodegenerative Measures

    MAYZENT WAS PROVEN TO SLOW PROGRESSION IN SPMS PATIENTS WITH ACTIVE DISEASE 1,25*

    The EXPAND trial was a randomized, double-blind, placebo-controlled, Phase III study of 1651 patients with...
page 

Pages

 of  3
×

Ask Speakers

×

Medical Information Request